GB201616511D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB201616511D0 GB201616511D0 GBGB1616511.0A GB201616511A GB201616511D0 GB 201616511 D0 GB201616511 D0 GB 201616511D0 GB 201616511 A GB201616511 A GB 201616511A GB 201616511 D0 GB201616511 D0 GB 201616511D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616511.0A GB201616511D0 (en) | 2016-09-29 | 2016-09-29 | Novel compounds |
| TW106132939A TWI766882B (zh) | 2016-09-29 | 2017-09-26 | 新穎化合物類 |
| CN201780059951.8A CN109790148B (zh) | 2016-09-29 | 2017-09-27 | 具有usp30抑制剂活性的氰基取代的杂环 |
| US16/336,363 US10927110B2 (en) | 2016-09-29 | 2017-09-27 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 |
| PCT/GB2017/052882 WO2018060691A1 (en) | 2016-09-29 | 2017-09-27 | Cyano-subtituted heterocycles with activity as inhibitors of usp30 |
| JP2019516577A JP7044769B2 (ja) | 2016-09-29 | 2017-09-27 | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換複素環 |
| EP17780148.7A EP3519397B1 (en) | 2016-09-29 | 2017-09-27 | Cyano-subtituted heterocycles with activity as inhibitors of usp30 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616511.0A GB201616511D0 (en) | 2016-09-29 | 2016-09-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201616511D0 true GB201616511D0 (en) | 2016-11-16 |
Family
ID=57571048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1616511.0A Ceased GB201616511D0 (en) | 2016-09-29 | 2016-09-29 | Novel compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10927110B2 (enExample) |
| EP (1) | EP3519397B1 (enExample) |
| JP (1) | JP7044769B2 (enExample) |
| CN (1) | CN109790148B (enExample) |
| GB (1) | GB201616511D0 (enExample) |
| TW (1) | TWI766882B (enExample) |
| WO (1) | WO2018060691A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| PL3860989T3 (pl) | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CN110759902B (zh) * | 2019-11-01 | 2022-04-22 | 海南一龄医疗产业发展有限公司 | Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途 |
| BR112022020058A2 (pt) | 2020-04-08 | 2022-11-22 | Mission Therapeutics Ltd | N-cianopirrolidinas com atividade como inibidores de usp30 |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| JP7796047B2 (ja) | 2020-06-04 | 2026-01-08 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
| DK4161929T3 (da) | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| CN112920124B (zh) * | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| CN118834147A (zh) * | 2021-09-22 | 2024-10-25 | 杭州天玑济世生物科技有限公司 | 一类具有萘胺结构的小分子化合物及其应用 |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| EP2152079A4 (en) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| PE20090606A1 (es) | 2007-08-20 | 2009-06-17 | Glaxo Group Ltd | Nuevos inhibidores de catepsina c y uso |
| PE20091888A1 (es) | 2008-04-18 | 2010-01-17 | Glaxo Group Ltd | Inhibidores de catepsina c |
| AR071480A1 (es) | 2008-04-18 | 2010-06-23 | Glaxo Group Ltd | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| CA2849194A1 (en) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
| CN105008344B (zh) * | 2012-11-02 | 2017-07-25 | 辉瑞公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| MX367085B (es) | 2013-07-31 | 2019-08-05 | Merck Patent Gmbh | Piridinas, pirimidinas y pirazinas como inhibidores de tirosina cinasa de bruton e inhibidores y usos de las mismas. |
| KR20160063366A (ko) * | 2013-10-21 | 2016-06-03 | 메르크 파텐트 게엠베하 | Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도 |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| EP3145505A4 (en) | 2014-05-19 | 2018-02-28 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
| WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| AR102426A1 (es) * | 2014-10-24 | 2017-03-01 | Bristol Myers Squibb Co | Compuestos de indolcarboxamida como inhibidores de btk |
| MY188957A (en) | 2015-03-30 | 2022-01-14 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| US10669234B2 (en) | 2015-07-14 | 2020-06-02 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| EP3436451B1 (en) | 2016-03-30 | 2021-09-29 | University Of Virginia Patent Foundation | Sphingosine kinase inhibitor amidoxime prodrugs |
| WO2017198050A1 (zh) | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物 |
| CN111153906B (zh) | 2016-05-16 | 2020-09-11 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
-
2016
- 2016-09-29 GB GBGB1616511.0A patent/GB201616511D0/en not_active Ceased
-
2017
- 2017-09-26 TW TW106132939A patent/TWI766882B/zh active
- 2017-09-27 CN CN201780059951.8A patent/CN109790148B/zh active Active
- 2017-09-27 JP JP2019516577A patent/JP7044769B2/ja active Active
- 2017-09-27 EP EP17780148.7A patent/EP3519397B1/en active Active
- 2017-09-27 WO PCT/GB2017/052882 patent/WO2018060691A1/en not_active Ceased
- 2017-09-27 US US16/336,363 patent/US10927110B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532945A (ja) | 2019-11-14 |
| US20190218215A1 (en) | 2019-07-18 |
| US10927110B2 (en) | 2021-02-23 |
| TWI766882B (zh) | 2022-06-11 |
| WO2018060691A1 (en) | 2018-04-05 |
| JP7044769B2 (ja) | 2022-03-30 |
| TW201825472A (zh) | 2018-07-16 |
| CN109790148A (zh) | 2019-05-21 |
| CN109790148B (zh) | 2022-06-07 |
| EP3519397B1 (en) | 2021-05-19 |
| EP3519397A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201614134D0 (en) | Novel compounds | |
| GB201610147D0 (en) | Novel compounds | |
| GB201616627D0 (en) | Novel compounds | |
| GB201604647D0 (en) | Novel compounds | |
| GB201604638D0 (en) | Novel compounds | |
| GB201602854D0 (en) | Novel compounds | |
| GB201603779D0 (en) | Novel compounds | |
| GB201602934D0 (en) | Compounds | |
| GB201613163D0 (en) | Novel compounds | |
| GB201610854D0 (en) | Compounds | |
| GB201604020D0 (en) | Compounds | |
| GB201604027D0 (en) | Compounds | |
| GB201622007D0 (en) | Polymorphs | |
| GB201613946D0 (en) | Compounds | |
| GB201608777D0 (en) | Compounds | |
| GB201604022D0 (en) | Compounds | |
| GB201604030D0 (en) | Compounds | |
| GB201619514D0 (en) | Novel compounds | |
| GB201618346D0 (en) | Novel compounds | |
| GB201615191D0 (en) | Novel compounds | |
| GB201601301D0 (en) | Novel compounds | |
| GB201604029D0 (en) | Compounds | |
| GB201622365D0 (en) | Compounds | |
| GB201604031D0 (en) | Compounds | |
| GB201616907D0 (en) | Novel Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |